![GSK_new_logo](https://pharmaphorum.com/wp-content/uploads/2022/06/GSK_new_logo.jpg)
GSK shelves arthritis blockbuster hope otilimab after lacklu...
GSK has said it will not be able to move ahead with regulatory filings for otilimab as a treatment for rheumatoid arthritis (RA), after it failed to show the desired level of efficacy in tw